GenomOncology
GenomOncology provides AI-enabled precision oncology software that transforms genomic and clinical data into actionable decision support for molecular pathologists, oncologists, bioinformaticians, and diagnostic laboratories across 50+ U.S. healthcare institutions.
- Company typePrivate
- Founded2012
- HeadquartersCleveland, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What GenomOncology does
GenomOncology is a Cleveland, Ohio-based precision oncology software company founded in 2012 that provides an AI-enabled platform translating next-generation sequencing and clinical data into actionable decision support for oncology professionals. The company serves 50+ healthcare institutions across the United States, including molecular pathology labs, comprehensive cancer centers, diagnostic companies, and health systems. Its core products are organized under the Precision Oncology Platform (POP) umbrella and include GO Pathology Workbench (tertiary variant analysis and customizable clinical reporting), GO Molecular Tumor Board (multidisciplinary decision support with embedded trial recommendations), Clinical Trial Matching (automated patient-to-trial matching across 15,000+ active trials), the Precision Oncology API Suite (bidirectional HL7 integration without middleware), igniteIQ (NLP/OCR data enablement that extracts and normalizes unstructured pathology reports and clinical notes), GenomAnalytics, and BioMCP, an open-source Model Context Protocol for biomedical AI assistants released in 2025.
Underlying technology combines AI/NLP pipelines tuned for biomedical text, OCR with biomedical spell correction and image cleaning, ontology-linked normalization against standards such as ICD-O, HGNC, MONDO, HPO, and LOINC, and a curated content library spanning FDA indications, clinical trials, and integrated third-party evidence such as Genomenon Mastermind. The platform supports HIPAA-compliant cloud and on-premise deployment and integrates directly with EHR systems (notably a first-of-its-kind MEDITECH Expanse Genomics integration), sequencing platforms (PacBio HiFi long-read WGS, Pillar Biosciences panels), and laboratory information systems.
The business model is subscription-based enterprise SaaS delivered primarily through direct enterprise field sales led by a Chief Commercial Officer, with a 5-step sales process (discovery, demo, technical review, proposal, implementation). Distribution is augmented by channel and OEM-style integrations with diagnostic laboratories (Belay Diagnostics, Chronetyx Laboratories, OHSU Knight Diagnostics Lab) that embed the platform into high-volume NGS workflows, and by EHR and sequencing-platform partnerships that expand reach without resellers. Pricing is not publicly disclosed and is quote-based. The company completed a Series B funding round in 2023, is structured as an Ohio LLC, and reports a headcount band of 51-100.
GenomOncology firmographics
Firmographics- Name
- GenomOncology
- Legal name
- GenomOncology LLC
- Website
- https://genomoncology.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GenomOncology provides AI-enabled precision oncology software that transforms genomic and clinical data into actionable decision support for molecular pathologists, oncologists, bioinformaticians, and diagnostic laboratories across 50+ U.S. healthcare institutions.
- Ownership category
- akta.pro rank
GenomOncology industry classification
Industry- Product category
- Precision Oncology Clinical Decision Support Software
- NAICS
- Software Publishers (5132), Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where GenomOncology is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GenomOncology business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Precision Oncology Platform Licensing: Software platform licensing model providing access to GO Pathology Workbench, Clinical Trial Matching, and Data Enablement solutions. Subscription-based pricing with implementation and support services.
- Enterprise Software Solutions: Comprehensive end-to-end software solutions for molecular pathology labs, clinical trial optimization, and data enablement delivered as integrated platform access.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
GenomOncology product offering
Product offeringCore offering
GenomOncology develops and licenses the Precision Oncology Platform (POP), an AI-enabled clinical decision support software suite for molecular pathology labs, oncologists, and researchers. Its core modules include GO Pathology Workbench for variant analysis and reporting, Clinical Trial Matching across 15,000+ trials, GO Molecular Tumor Board, and igniteIQ for data enablement via NLP/OCR. The platform integrates directly with EHR, LIS, and LIMS systems using HL7 and is offered as cloud or on-premise subscriptions.
Product overview
GenomOncology offers the Precision Oncology Platform (POP), a unified platform architecture comprising multiple integrated solutions. The core offerings include GO Pathology Workbench for molecular pathology reporting and variant analysis, Clinical Trial Matching for automated patient-trial matching across 15,000+ trials, GO Molecular Tumor Board for multidisciplinary decision support, igniteIQ for data enablement and NLP/OCR extraction, GenomAnalytics for institutional analytics, and BioMCP for biomedical AI integration. The platform supports both cloud and on-premise deployment with direct HL7/EHR integration without middleware. The three main solution areas are Molecular Pathology Solutions (GO Pathology Workbench, GO Connect), Clinical Trial Optimization (Clinical Trial Matching, GO Molecular Tumor Board, Precision Oncology API Suite), and Data Enablement (igniteIQ, GenomAnalytics).
Differentiator
Problem solved
Functional benefit
Brands
- GO Pathology Workbench: Clinical genomic data analysis and reporting platform for molecular pathology labs.
- BioMCP
- igniteIQ
- Precision Oncology Platform (POP)
Products and services
- GO Pathology Workbench
- GO Connect
- Clinical Trial Matching
- GO Molecular Tumor Board
- Precision Oncology API Suite
- igniteIQ
- GenomAnalytics
- BioMCP
Quantifiable outcome
- 3x increase in clinical trial enrollment at early adopter institutions
- +4 more outcomes
Companies that use GenomOncology
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
GenomOncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability9 records
Feature6 records
GenomOncology partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, strategic and major.
- WeTrialscoreStrategic partnership embedding WeTrials' AI-powered patient engagement platform directly within GO Genomic Reports. Enables clinicians to move from molecular reports with matched trial recommendations directly into WeTrials' patient-friendly trial enrollment interface. Initial focus on CNS cancer patients tested through Belay Diagnostics, with expansion planned to additional diagnostic partners and cancer types.
- OHSU Knight Diagnostics LabcoreImplementation of GO Clinical Trials Matching Solution integrating directly into KDL's diagnostic workflow. Automatically matches patients to open trials based on molecular profiles and clinical characteristics. Enables pathologists to generate customized matches within minutes rather than hours or days.
- Glioblastoma FoundationcorePathology Workbench platform integrated into Foundation's new genomic testing laboratory for glioblastoma. Operational within two weeks of contract signing. Supports comprehensive genomic panel testing, RNA fusion analysis, and whole genome sequencing methylation testing for MGMT.
- PacBiostrategicIntegrated end-to-end workflow combining PacBio HiFi whole-genome sequencing with GenomOncology Pathology Workbench for clinical labs. Supports configurable, reimbursement-aligned genomic reports across tumor types.
- Chronetyx LaboratoriesmajorPathology Workbench integration as tertiary analysis platform supporting Chronetyx Laboratories' FDA cleared Cyx Solid Tumor 505 test. Significantly reduces turnaround times by eliminating manual processes and automating complex genomic interpretations.
- Belay DiagnosticscoreGO Pathology Workbench integrated into Belay Diagnostics' variant interpretation workflow for Summit liquid biopsy test. Supports thousands of samples per month for CNS cancer detection. Partnership reduces laboratory overhead and accelerates review, providing faster access to treatment recommendations.
- Pillar BiosciencesmajorCo-marketing partnership integrating GenomOncology's clinical decision support platform with Pillar's research-use-only targeted NGS panels. Enables seamless workflow from NGS sequencer to clinical report with combined genomic data and decision support.
- GenomenonmajorIntegration of Genomenon's Mastermind Data into GenomOncology's knowledgebase for enhanced germline variant classification. Content includes evidence supporting variant classifications, gene-disease relationships, and evidence automations aligned with ACMG guidelines and ClinGen standards.
- MEDITECHcoreIntegration between MEDITECH Expanse Genomics solution and GenomOncology Precision Oncology Platform. Embeds comprehensive precision medicine information including treatment recommendations and clinical trials within Expanse EHR workflow. First-of-its-kind integration driving targeted cancer treatments.
- City of HopemajorData enablement partnership using GenomOncology's igniteIQ solution within City of Hope's POSEIDON platform. NLP-based clinical data integration with expert-in-the-loop model for biomarker normalization and structure detection.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
GenomOncology competitors and assessment
Company assessmentBroad incumbents
- Flatiron Health: Flatiron Health (acquired by Roche) is a leading oncology-specific EHR and real-world data platform serving community oncology practices, academic centers, and life sciences companies. It directly overlaps with GenomOncology in clinical decision support, molecular profiling interpretation, and trial matching — but at much larger scale and with deeper pharma relationships.
- Tempus Labs: Tempus is an AI-enabled precision medicine platform offering NGS profiling, clinical trial matching, and decision support across oncology. Like GenomOncology, Tempus operates a molecular pathology interpretation layer and clinical trial matching engine, but with a much broader biopharma-services business and larger capital base.
- Foundation Medicine: Foundation Medicine (acquired by Roche) provides comprehensive genomic profiling and a molecular knowledge base widely used by oncologists. It competes with GenomOncology's Pathology Workbench on variant interpretation, but typically upstream of tertiary analysis as the test provider rather than the software platform layer.
- Philips Digital Pathology: Philips offers an enterprise digital pathology suite (IntelliSite) plus broader oncology informatics used by hospitals and pathology networks. It competes more broadly with GenomOncology in pathology workflow and oncology decision support, but as part of a much wider imaging and clinical informatics portfolio.
Direct peers
- SOPHiA Genetics: SOPHiA Genetics offers a genomics interpretation platform used by hospitals and labs worldwide for variant calling and clinical reporting across hereditary oncology, solid tumors, and rare disease. It is a direct competitor to GenomOncology's GO Pathology Workbench and igniteIQ, with a comparable SaaS-to-labs model.
- Velsera (formerly Seven Bridges): Velsera provides a clinical genomics cloud informatics platform including tertiary analysis, NGS workflows, and decision support for molecular pathology labs. It is a direct competitor to GenomOncology's Precision Oncology Platform, particularly with hospital and academic medical center labs.
- Pierian (acquired by Illumina/Agilent): Pierian was a clinical genomics interpretation and reporting platform for molecular pathology labs before its acquisition; GenomOncology's CCO Garreth Hippe previously led commercial growth at Pierian. It is a near-identical competitive reference point for GO Pathology Workbench.
- Molecular Health: Molecular Health offers a precision medicine decision support platform — including MH Guide for clinical interpretation of genomic variants and Dataome for biomedical knowledge — competing directly with GenomOncology's Pathology Workbench and Clinical Trial Matching offerings.
- Inspirata: Inspirata provides a digital pathology workflow and oncology case-management platform used by pathology labs and cancer centers. It overlaps with GenomOncology in molecular pathology workflow automation and oncology decision support for labs and tumor boards.
Emerging players
- 2bPrecise: 2bPrecise (now part of Tempus) embeds precision medicine and pharmacogenomics decision support directly into the EHR. It is a comparable peer to GenomOncology's MEDITECH/Expanse integration approach and a relevant competitor for in-EHR oncology CDS.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
GenomOncology social profiles
Digital presenceGenomOncology compliance and trust
Trust signalCompliance1 record
GenomOncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenomOncology leadership team
Management profileNumber of profiles
Profiles15 records
GenomOncology funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenomOncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenomOncology
What does GenomOncology do?
GenomOncology develops and licenses the Precision Oncology Platform (POP), an AI-enabled clinical decision support software suite for molecular pathology labs, oncologists, and researchers. Its core modules include GO Pathology Workbench for variant analysis and reporting, Clinical Trial Matching across 15,000+ trials, GO Molecular Tumor Board, and igniteIQ for data enablement via NLP/OCR. The platform integrates directly with EHR, LIS, and LIMS systems using HL7 and is offered as cloud or on-premise subscriptions.
Is GenomOncology a public or private company?
GenomOncology is a private company. It is classified as venture growth investor backed and is currently operating.
When was GenomOncology founded?
GenomOncology was founded in 2012. It employs 51 to 100 people.
Where is GenomOncology based?
GenomOncology is headquartered in Cleveland, United States, in the North America region.
How does GenomOncology make money?
Two revenue lines are on record. Precision Oncology Platform Licensing is the primary driver. The others are enterprise Software Solutions.
Who are GenomOncology's main competitors?
Broad incumbents on record are Flatiron Health, Tempus Labs, Foundation Medicine and Philips Digital Pathology. Direct peers are SOPHiA Genetics, Velsera (formerly Seven Bridges), Pierian (acquired by Illumina/Agilent), Molecular Health and Inspirata. 2bPrecise is listed as an emerging player.
Does GenomOncology have an API?
Yes. GenomOncology offers API capabilities including the Precision Oncology API Suite which enables clinical trial matching, therapy recommendations, and genomic data exchange. The platform supports bidirectional HL7 integration with no middleware required, allowing direct EHR integration for automated order acceptance and discrete genomic findings delivery. The platform also offers BioMCP, an open-source Model Context Protocol implementation for biomedical AI assistants and agents that supports advanced searching and full-text retrieval from clinical trials, genetic data, and published medical research. Developer documentation is at biomcp.org.
What industry is GenomOncology in?
GenomOncology's product category is Precision Oncology Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5132 and its SIC code is 7372.